Other safety alerts
|
| |
| Australia: TGA warning on the risks of importing unapproved peptide products |
| |
The Therapeutic Goods Administration (TGA) is warning consumers about the risks of importing and using unapproved peptide products that are promoted online.
The TGA continues to see peptide products imported through the Personal Importation Scheme. These products may pose significant risks to patient safety.
Products referred to the TGA by the Australian Border Force (ABF) are often poorly labelled. This makes it impossible to verify their contents, and mean they may be products that put your health at serious risk.
The TGA has identified imported products suspected to be peptides that:
• are not included in the Australian Register of Therapeutic Goods (ARTG)
• are supplied as powders or injectables in unmarked vials, and
• are not clearly labelled and therefore cannot be identified, are marked only with codes or abbreviations, or are missing essential information such as the name and concentration of the active ingredient or dosing instructions.
Importing unapproved peptide products under the Personal Importation Scheme is permitted only if the goods are clearly and accurately labelled to identify the therapeutic good. For examples of insufficiently labelled, unsafe or non-compliant products, please refer to the TGA website.
Professor Anthony Lawler, Deputy Secretary of the Department of Health, Disability and Ageing and head of the TGA, said " Australians should be very cautious about buying peptide products online, particularly from overseas websites or through online platforms or social media.
“Many of these products are unapproved, poorly labelled and not subject to Australian safety or quality standards. If you don’t know exactly what’s in the vial, where it was made or whether it’s sterile, you could be putting your health at serious risk. You could also incur financial loss if the product is intercepted at the border and cannot be lawfully released.”
Professor Robyn Langham AM, the TGA’s Chief Medical Advisor, said “the biggest risks with unapproved peptide products are not knowing what’s in the vial. There is no way of knowing how much of the peptide is in there, whether the contents are sterile or whether there are other contaminants or toxins in there that you risk administering to yourself.
“Unmarked vials, code only labels, or missing ingredient and dosing information are major red flags. To reduce your risk, you should buy therapeutic goods only from a legitimate Australian pharmacy or supplier, and talk to your doctor or another health professional, especially before using injectable products.”
Consistent with TGA requirements, these vials will not be released under the Personal Importation Scheme.
Please refer to the following website in TGA for details:
http://www.tga.gov.au/safety/safety-monitoring-and-information/../tga-warning-risks-importing-unapproved-peptide-products
In Hong Kong, the peptide products as mentioned in the above TGA announcement are not registered pharmaceutical products. Related news was previously issued by Health Canada and TGA, and was posted on the Drug Office website on 10 Apr 2026 and 13 Apr 2026 respectively. The DH will remain vigilant on safety update of peptide products issued by other drug regulatory authorities.
Ends/Friday, May 8, 2026
Issued at HKT 14:30
|
| |
